MBX Biosciences’ weekly canvuparatide meets primary endpoint in Phase 2 trial

MBX Biosciences announced that its once-weekly investigational drug, canvuparatide, achieved the prespecified primary composite endpoint in its Phase 2 Avail trial in patients with chronic hypoparathyroidism, according to the company. In the 12-week randomized period, 63 % of canvuparatide-treated p…